FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2123670663> ?p ?o ?g. }

• W2123670663 endingPage "173" @default.
• W2123670663 startingPage "163" @default.
• W2123670663 abstract "Object The preponderance of progesterone receptors (PRs) and the scarcity of estrogen receptors (ERs) in meningiomas are well known. The expression of PRs may relate to tumor grade and recurrence. Cytogenetic abnormalities are associated with aggressive behavior, recurrence, and progression. In this study, the authors focus on the prognostic implications of hormone receptors in meningiomas to help determine the clinical and biological aggressiveness of tumors and their correlations with cytogenetic abnormalities. Methods Two hundred thirty-nine patients with meningiomas were separated into three groups. Group 1 (PR-positive group) comprised patients whose meningiomas displayed expression of PRs alone. Group 2 (receptor-negative group) included patients whose lesions did not have receptors for either progesterone or estrogen. Group 3 (ER-positive group) included patients whose tumors displayed expression of ERs. Clinical and histological findings, proliferative indices, tumor recurrence, and cytogenetic findings were analyzed by performing the Fisher exact test. Compared with the receptor-negative (Group 2) and ER-positive (Group 3) groups, the PR-positive group (Group 1) had a statistically significant lower proliferative index and a smaller number of patients in whom there were aggressive histopathological findings or changes in karyotype. In Groups 1, 2, and 3, the percentages of cases with aggressive histopathological findings were 10, 31, and 33%, respectively; the percentages of cases with chromosomal abnormalities were 50, 84, and 86%, respectively; and the percentages of cases in which there initially was no residual tumor but recurrence was documented were 5, 30, and 27%, respectively. A statistically significant increase in the involvement of chromosomes 14 and 22 was identified in receptor-negative and ER-positive de novo meningiomas, when compared with the PR-positive group. Abnormalities on chromosome 19 were statistically significantly higher in receptor-negative meningiomas than in PR-positive tumors. Conclusions The expression of the PR alone in meningiomas signals a favorable clinical and biological outcome. A lack of receptors or the presence of ERs in meningiomas correlates with an accumulation of qualitative and quantitative karyotype abnormalities, a higher proportional involvement of chromosomes 14 and 22 in de novo tumors, and an increasing potential for aggressive clinical behavior, progression, and recurrence of these lesions. Sex hormone receptor status should routinely be studied for its prognostic value, especially in female patients, and should be taken into account in tumor grading. The initial receptor status of a tumor may change in progression or recurrence of tumor." @default.
• W2123670663 created "2016-06-24" @default.
• W2123670663 creator A5037506643 @default.
• W2123670663 creator A5039234509 @default.
• W2123670663 creator A5069473248 @default.
• W2123670663 creator A5073180479 @default.
• W2123670663 date "2006-08-01" @default.
• W2123670663 modified "2023-10-14" @default.
• W2123670663 title "Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas" @default.
• W2123670663 cites W132680443 @default.
• W2123670663 cites W1521971423 @default.
• W2123670663 cites W188267201 @default.
• W2123670663 cites W1963508923 @default.
• W2123670663 cites W1968819356 @default.
• W2123670663 cites W1968920447 @default.
• W2123670663 cites W1970056377 @default.
• W2123670663 cites W1974208182 @default.
• W2123670663 cites W1975890657 @default.
• W2123670663 cites W1979466151 @default.
• W2123670663 cites W1980027625 @default.
• W2123670663 cites W1985314580 @default.
• W2123670663 cites W1986846967 @default.
• W2123670663 cites W1987194339 @default.
• W2123670663 cites W1989622889 @default.
• W2123670663 cites W1990786155 @default.
• W2123670663 cites W2010121586 @default.
• W2123670663 cites W2010916643 @default.
• W2123670663 cites W2012861492 @default.
• W2123670663 cites W2013646995 @default.
• W2123670663 cites W2015176155 @default.
• W2123670663 cites W2015824512 @default.
• W2123670663 cites W2016146828 @default.
• W2123670663 cites W2025281994 @default.
• W2123670663 cites W2025519084 @default.
• W2123670663 cites W2025619919 @default.
• W2123670663 cites W2034122020 @default.
• W2123670663 cites W2041025015 @default.
• W2123670663 cites W2048973341 @default.
• W2123670663 cites W2049117179 @default.
• W2123670663 cites W2050229641 @default.
• W2123670663 cites W2051215110 @default.
• W2123670663 cites W2052573587 @default.
• W2123670663 cites W2053396174 @default.
• W2123670663 cites W2054509023 @default.
• W2123670663 cites W2055147918 @default.
• W2123670663 cites W2056834448 @default.
• W2123670663 cites W2060128629 @default.
• W2123670663 cites W2062336733 @default.
• W2123670663 cites W2063055944 @default.
• W2123670663 cites W2063469492 @default.
• W2123670663 cites W2066982375 @default.
• W2123670663 cites W2067167454 @default.
• W2123670663 cites W2067992371 @default.
• W2123670663 cites W2069143048 @default.
• W2123670663 cites W2072103745 @default.
• W2123670663 cites W2073412244 @default.
• W2123670663 cites W2074551928 @default.
• W2123670663 cites W2074838987 @default.
• W2123670663 cites W2082785713 @default.
• W2123670663 cites W2091164615 @default.
• W2123670663 cites W2092915247 @default.
• W2123670663 cites W2097589013 @default.
• W2123670663 cites W2100167123 @default.
• W2123670663 cites W2107612375 @default.
• W2123670663 cites W2111340022 @default.
• W2123670663 cites W2113167195 @default.
• W2123670663 cites W2155885258 @default.
• W2123670663 cites W2158835756 @default.
• W2123670663 cites W2165927109 @default.
• W2123670663 cites W2170382829 @default.
• W2123670663 cites W2309042391 @default.
• W2123670663 cites W2331269436 @default.
• W2123670663 cites W2614551048 @default.
• W2123670663 cites W2800400222 @default.
• W2123670663 cites W3080295864 @default.
• W2123670663 cites W3140666778 @default.
• W2123670663 cites W4376595513 @default.
• W2123670663 doi "https://doi.org/10.3171/jns.2006.105.2.163" @default.
• W2123670663 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17219818" @default.
• W2123670663 hasPublicationYear "2006" @default.
• W2123670663 type Work @default.
• W2123670663 sameAs 2123670663 @default.
• W2123670663 citedByCount "148" @default.
• W2123670663 countsByYear W21236706632012 @default.
• W2123670663 countsByYear W21236706632013 @default.
• W2123670663 countsByYear W21236706632014 @default.
• W2123670663 countsByYear W21236706632015 @default.
• W2123670663 countsByYear W21236706632016 @default.
• W2123670663 countsByYear W21236706632017 @default.
• W2123670663 countsByYear W21236706632018 @default.
• W2123670663 countsByYear W21236706632019 @default.
• W2123670663 countsByYear W21236706632020 @default.
• W2123670663 countsByYear W21236706632021 @default.
• W2123670663 countsByYear W21236706632022 @default.
• W2123670663 countsByYear W21236706632023 @default.
• W2123670663 crossrefType "journal-article" @default.
• W2123670663 hasAuthorship W2123670663A5037506643 @default.
• W2123670663 hasAuthorship W2123670663A5039234509 @default.

• next